Robert G. Maki
- PROFESSOR Hematology/Oncology
- PROFESSOR Hematology and Medical Oncology
- PROFESSOR Orthopaedics
Print Profile
Certifications
Medical Oncology
American Board of Internal Medicine
Clinical Focus
Education
MD, Cornell University Medical College
PhD, Cornell Graduate School of Medical Sciences
Immunology / Molecular BiologyResidency, Internal Medicine
Brigham and Women's HospitalFellowship, Medical Oncology
Dana Farber Cancer Institute
Biography
Dr. Robert Maki is Professor of Medicine, Pediatrics, and Orthopaedics, and the Steven Ravitch Chair in Pediatric Hematology-Onocology. He has published more than 100 articles on sarcoma treatment and basic science research, having worked on studies related to sarcoma since 1985. He treats adults and children with sarcomas (connective tissue cancers of bone, cartilage, muscle, fat and other soft tissue) and has an interest in translational research and the biology that leads to different types of sarcomas.
After his MD/PhD at Cornell Medical College in New York City, he was a resident at Brigham and Women's Hospital in Boston before a medical oncology fellowship at Dana-Farber, and was on staff at Dana-Farber before starting at Memorial Sloan-Kettering in 1999. In March, 2011 he moved to the Mount Sinai Medical Center to develop the effort in adult sarcoma therapy and research.
Dr. Maki's efforts at Mount Sinai will be directed towards an increasingly integrative effort sarcoma biology and treatment of sarcomas. His group will conduct clinical trials in adults with sarcomas, and they will also conduct translational studies in sarcoma biology to identify the next possible targets for new drugs to treat sarcomas.
Dr Maki now also leads the Pediatric Hematology-Oncology program at Mount Sinai, and will continue his personal interest in the care of adolescents with sarcomas, while also expanding the role of the pediatric hematology-oncology program in the treatment and research of pediatric cancers such as acute lymphoblastic leukemia, as well as "benign" but often life-threatening hematologic conditions.
Awards
2009 - 2011
NCI-ASCO Clinical Investigator Team Leadership Award
National Cancer Institute & American Society for Clinical Oncology
Research
Developmental chemotherapeutics
Topics include:
- Phase I-II-III clinical trials
- Novel approaches, e.g. Bayesian designs, to accelerate drug development
- Pharmacokinetics, pharmacodynamics, pharmacogenomics
Treatment of sarcomas of soft tissue and bone
Examples include:
- GIST (gastrointestinal stromal tumor)
- Leiomyosarcoma
- "UPS"/"MFH": undifferentiated pleomorphic sarcoma / malignant fibrous histiocytoma
- Myxofibrosarcoma
- Synovial sarcoma
- Myxoid/round cell liposarcoma
- Well differentiated/dedifferentiated liposarcoma
- Pleomorphic liposarcoma
- Angiosarcoma, Epithelioid hemangioendothelioma, and other vascular tumors
- Spindle cell sarcoma not otherwise specified (NOS)
- Uterine sarcomas (such as leiomyosarcoma, endometrial stromal sarcoma, high grade undifferentiated uterine sarcoma, carcinosarcoma or mixed mullerian tumor)
- Osteogenic sarcoma (osteosarcoma)
- Ewing sarcoma
- Chondrosarcoma
- Ewing sarcoma
- Malignant peripheral nerve sheath tumor (MPNST)
- Desmoplastic small round cell tumor (DSRCT)
- Epithelioid sarcoma
- PEComa (perivscular epithelial cell tumor)
- Fibromyxoid sarcoma (Evans' tumor)
- Phyllodes tumor of the breast
- Chordoma
- Small round blue cell tumors
- Rhabdomyosarcoma
- Lymph node sustentacular tumor (follicular dendritic cell tumor, interdigitating reticular cell tumor, Langerhans cell histiocytosis)
- Alveolar soft part sarcoma (ASPS)
- Clear cell sarcoma (of tendon sheath)
Treatment of locally aggressive connective tissue tumors
Examples include:
- Deep fibromatosis/desmoid tumor, superficial fibromatosis
- Tenosynovial giant cell tumor/pigmented villonodular synovitis (TGCT/PVNS)
- Giant cell tumor of bone
- Angiomyxoma, angiofibroma, angiomatoid fibrous histiocytoma
- Giant hemangiomas
Translational sarcoma research
Examples include:
- In vivo models of sarcomas
- Genomic analysis of sarcoma subtypes
- Identification of novel drug targets and therapeutics
- Novel imaging modalities
Industry Relationships
Physicians and scientists on the faculty of Mount Sinai School of Medicine often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Maki during 2011 and/or 2012. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- Eli Lilly and Company; Pfizer Inc.
Scientific Advisory Board:
- Eisai Inc.; GlaxoSmithKline; Novartis; ZIOPHARM Oncology, Inc.; sanofi-aventis
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://www.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Annenberg Building Floor 4 Room 4-52
1468 Madison Avenue
New York, NY 10029
Fax: 212-360-6921
Ruttenberg Treatment Center
1190 5th Avenue, Main Level
New York, NY 10029
- Master Card
- Visa
- Credit Card (Other)
1468 Madison Avenue
Annenberg Building, 4th flr., room 52
New York, NY 10029
- Master Card
- Visa
- Credit Card (Other)